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Available online 24 November 2010AbstractPurpose: Breast-conserving surgery (BCS) results in tumour-positive surgical margins in up to 40% of the patients. Therefore, new imaging
techniques are needed that support the surgeon with real-time feedback on tumour location and margin status. In this study, the potential of
near-infrared fluorescence (NIRF) imaging in BCS for pre- and intraoperative tumour localization, margin status assessment and detection
of residual disease was assessed in tissue-simulating breast phantoms.
Methods: Breast-shaped phantoms were produced with optical properties that closely match those of normal breast tissue. Fluorescent tu-
mour-like inclusions containing indocyanine green (ICG) were positioned at predefined locations in the phantoms to allow for simulation of
(i) preoperative tumour localization, (ii) real-time NIRF-guided tumour resection, and (iii) intraoperative margin assessment. Optical im-
aging was performed using a custom-made clinical prototype NIRF intraoperative camera.
Results: Tumour-like inclusions in breast phantoms could be detected up to a depth of 21 mm using a NIRF intraoperative camera system.
Real-time NIRF-guided resection of tumour-like inclusions proved feasible. Moreover, intraoperative NIRF imaging reliably detected re-
sidual disease in case of inadequate resection.
Conclusion: We evaluated the potential of NIRF imaging applications for BCS. The clinical setting was simulated by exploiting tissue-like
breast phantoms with fluorescent tumour-like agarose inclusions. From this evaluation, we conclude that intraoperative NIRF imaging is
feasible and may improve BCS by providing the surgeon with imaging information on tumour location, margin status, and presence of
residual disease in real-time. Clinical studies are needed to further validate these results.Synopsis: Near-infrared fluorescence (NIRF)-based tumour imaging has great potential for improving breast-conserving 201
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doi:10.surgery. In this report, intraoperative NIRF applications were preclinically evaluated using tissue-simulating
breast phantoms equipped with fluorescent tumour-like inclusions of different size and shape in breast-conserving
surgery simulations.
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Breast cancer is the most frequent malignancy in women
worldwide with an estimated 1.4 million new cases in
2010.1 Breast-conserving therapy (BCT), consisting of
breast-conserving surgery (BCS) followed by radiation
therapy, has become the standard treatment for T1eT2
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this subset of patients.2 Unfortunately, a majority of studies
on the surgical margin status after BCS have shown that
positive margins are detected in 20e40% of patients, neces-
sitating additional surgical intervention or radiotherapy.3
Two major points for improving outcome after BCS involve
(i) a more reliable intraoperative tumour localization and
(ii) improved real-time feedback on the presence of possi-
ble residual disease during or after excision of the tumour.4
Intraoperative application of an optical imaging technique
known as near-infrared fluorescence (NIRF) imaging may
improve the clinical outcome of BCS.3,5Near-infrared fluorescence imagingIn recent years, significant progress has been made in the
development of optical imaging systems and fluorophores
for clinical applications.6,7 Several animal5,8e10 and clin-
ical11e15 studies have shown the potential clinical use of
NIRF imaging to improve the therapeutic outcome of sur-
gery. Compared to light in the visible spectral range
(400e650 nm), application of near-infrared (NIR) light
minimizes absorption by physiologically abundant mole-
cules such as hemoglobin and lipids, which increases
penetration depth.16,17 Additionally, autofluorescence (the
intrinsic fluorescence signal present in all living cells due
to various normal metabolites and tissue constituents) is
strongly reduced in the NIR spectral range. Taken together,
these aspects of NIR light make it particularly suitable for
use in intraoperative optical imaging applications. How-
ever, clinical application of NIRF imaging in BCS is cur-
rently limited to the non-specific intraoperative detection
of the sentinel lymph node.11,12,14,18e20Tumour-targeted near-infrared fluorophoresWith the introduction of clinical grade tumour-targeted
NIR fluorophores, NIRF imaging may be extended towards
the intraoperative detection of the primary tumour.10 Sev-
eral target molecules have been identified for breast cancer
that may be of value for such an approach, including Her2/
neu receptor,9,21,22 vascular endothelial growth factor
(VEGF) receptor,23,24 endothelial growth factor (EGF) re-
ceptor25 and folate receptor-a.26
In tumour-targeted NIRF imaging, a tumour-targeted
NIR fluorophore is administered several hours or days prior
to the imaging procedure. Subsequently, an external laser is
used to irradiate the breast with light in the NIR spectral
range (650e900 nm).17 Upon excitation, the fluorophore
will release photons of a higher NIR wavelength. Because
NIR light is invisible to the naked eye, a dedicated optical
imaging system is necessary to capture the NIR signal from
the surgical field and digitally convert it to a visible image.
Recently, we and our co-workers developed a multispectral
NIRF intraoperative camera system that is suitable for
intraoperative use with NIR fluorophores.27Simulation of NIRF-guided breast-conserving
surgeryIn the current preclinical study, we evaluated intraopera-
tive NIRF imaging applications in a simulated clinical setting
as a step-up toward NIRF-guided BCS. To this end, we used
tissue-simulating gelatin-based breast phantoms that mimic
the optical properties of normal breast tissue.28,29 Tumour-
like fluorescent inclusions of different size and shape were
positioned at predefined sites in the phantoms, allowing for
simulation of (i) preoperative tumour localization, (ii) real-
time NIRF-guided tumour resection and (iii) intraoperative
macroscopic margin assessment. The tumour-like inclusions
contain the non-specific NIR fluorophore indocyanine green
(ICG), to simulate for the use of tumour-targeted near-infra-
red fluorophores in BCS. Currently, ICG (absorption and
emission maximum at w780 and w820 nm, respectively)
is one of the few FDA-approved NIR fluorophores available
for clinical use.9 Sevick-Muraca et al. have previously shown
the feasibility of NIRF imaging following microdose admin-
istration of ICG.12Although ICG in itself is non-specific, their
findings suggest that comparable microdose concentrations
can be used to label cancer cells with tumour-targeted NIR
fluorophores for intraoperative NIRF imaging. Importantly,
new fluorophores in the NIR spectral range are currently be-
ing developed, e.g. IRDye 800CW, with properties more
promising for intraoperative use compared to ICG.25
Material and methodsAssessment of ICG fluorescence self-quenching in
agaroseBecause increasing concentrations of ICG may not cor-
respond to an increased fluorescence signal due to self-
quenching of ICG, different concentrations of ICG in
agarose were evaluated for fluorescence activity.29,30
Briefly, an ICG stock solution was serially diluted in
10 ml sterile water (ranging from 0.5 uM to 350 uM
ICG), after which 2% agarose was added. The mixture
was then heated to 70 C and stirred until the agarose
was completely dissolved. After solidification of the aga-
rose mixture for 15 min at 4 C, NIRF epi-illumination im-
aging was performed to determine maximum photon
counts/sec (settings: exposure time: 1000 ms, excitation:
780 nm, emission: 820 nm).Assessment maximal penetration depth of ICG
fluorescenceIn order to determine the maximal penetration depth of
the NIRF signal, a cubic fluorescent inclusion of
5  5  5 mm containing 14 mM ICG was positioned in
phantom tissue at a depth of 30 mm. Subsequently, the sur-
geon excised 3e4 mm layers of phantom tissue towards the
inclusion (remaining depths were 27, 24, 21, 18, 15, 11, 7,
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tion imaging was performed with the intraoperative NIRF
camera system (exposure time: 3000e60000 ms, excitation
780 nm, emission 820 nm, binning: small-medium). Maxi-
mum photon counts per second exposure time were calcu-
lated as well as the full width at half maximum (FWHM) of
the fluorescence signal. The FWHM is a measure for scat-
tering and indicates the diameter of the fluorescence signal
when the intensity of the signal is reduced to half the max-
imum. Scattering both contributes to signal loss and loss in
resolution. The FWHM indicates the minimal distance be-
tween two distinct sources to be recognized as separate.Tissue-simulating breast phantomsComposition of the tissue-simulating gelatin-based
breast phantoms was aimed at obtaining uniform optical
properties that closely match the optical characteristics of
normal breast tissue, as described in detail before.29 Addi-
tionally, the breast phantoms mimic the elastic properties of
human tissue.31
Briefly, 10% gelatin 250 (Natural Spices, Watergang, the
Netherlands) was dissolved in 1 l TBS (50 mmol TriseHCl,
150 mmol NaCl, pH 7.4). To remove molecular oxygen
and prevent microbial infection, 15 mmol NaN3 (Merck,Figure 1. Fluorescent tumour-like agarose inclusions differing in size and shape
Preoperatively, the location of the tumour-like inclusion was assessed non-invasi
excised under real-time NIRF guidance or guided solely by visual and tactile infor
was applied to inspect for residual disease and evaluate the extend of surgery (CDarmstadt, Germany) was added. The gelatin slurry was
completely dissolved by heating to 50 C and subsequently
cooled down to 35 C and maintained at this temperature.
Under constant stirring, 170 mmol hemoglobin (Sigmae
Aldrich, Zwijndrecht, The Netherlands) and 1% Intralipid
20% (SigmaeAldrich) were added. Next, the gelatin
mixture was poured in a custom-made pre-chilled breast-
shaped mold (end volume: 500 ml) to a level that corre-
sponded to the predefined depth of the agarose inclusion.
After solidification for 30 min at 4 C, a tumour-like NIR
fluorescent agarose inclusion was positioned on the surface
and temporarily fixed with a small needle. Next, the re-
maining of the warmed gelatin mixture was added to fill
up the remaining mold volume, allowing for adherence of
both layers. The phantom was then stored in the dark to so-
lidify for another 30 min at 4 C, after which it was gently
removed from its mold.
In total, 4 breast phantoms were constructed with tu-
mour-like NIR fluorescent agarose inclusions of different
size and shape (Figure 1A) positioned at predefined depths.
Imaging of the phantoms was performed directly after pro-
duction of all 4 phantoms.
Breast phantom #1 contained 2 similar-sized (Ø1.0 cm)
sphere-shaped agarose inclusions at different depths
(2.0 and 4.0 cm). Phantom #2 contained 2 sphere-shaped(AIeIII) were integrated in breast-shaped phantoms (CI) prior to surgery.
vely using a NIRF camera system (B). Intraoperatively, the inclusion was
mation (CII). At the end of the surgical procedure, the NIRF camera system
III).
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(Ø0.5 cm and Ø2.0 cm). Phantom #3 contained 1 sphere-
shaped (Ø1.0 cm) and 1 prolate sphere-shaped (Ø1.0 cm)
agarose inclusion at the same depth (1.5 cm). Finally, phan-
tom #4 contained 2 irregular shaped agarose inclusions of
similar size (Ø1.5 cm) at different depths (1.5 and 3.0 cm).Tumour-like NIR fluorescent agarose inclusionsFor tumour-like NIR fluorescent agarose inclusions, 2%
agarose (Hispanagar, Burgos, Spain) was used instead of
10% gelatin. Agarose has a higher melting point which pre-
vents the inclusions from dissolving and leaking ICG (see
below) during and after the positioning procedure in the
gelatin phantom. In short, a 2% (W/V) agarose slurry was
heated to 70 C and stirred until the agarose was completely
dissolved. Subsequently, ICG (ICG-PULSION; Pulsion
Medical Systems, Munich, Germany) was dissolved to
a final concentration of 14 mM. Finally, in order to resemble
the optical appearance of the surrounding breast phantom
tissue, 170 mM hemoglobin, 15 mM NaN3 and 1% Intra-
lipid 20% were added to the tumour-like fluorescent
inclusions.
Tumour-like fluorescent inclusions of different size
(range: 0.5 cme2.0 cm) and shape (prolate sphere, sphere
and irregular shape, Figure 1A) were produced. The inclu-
sions were integrated in the breast phantoms as indicated
and chilled in the dark for 30 min at 4 C. Imaging of
each individual breast phantom was performed within 6 h.Figure 2. Fluorescence signal intensity related to depth-location in tissue-like pha
in phantom tissue (A). Depth (mm) of the inclusion and maximum photon counts
respectively. Moreover, scattering of the fluorescence signal is shown (B), with d
vertical axis, respectively. For determination of the NIRF signal penetration dept
excised 3e4 mm tissue layers, working his way towards a fluorescent inclusion
clusion depth, no NIRF signal could be detected (not shown). Images were corrNear-infrared fluorescence imaging systemA custom-made NIRF camera system was developed in
collaboration with SurgOptix Inc (SurgOptix Inc, Redwood
Shores, CA, USA) for real-time intraoperative imaging.
The system implements a correction scheme that improves
the accuracy of epi-illumination fluorescence images for
light intensity variations in tissue. Implementation is based
on the use of three cameras operating in parallel. The camera
is mounted on a five degrees of freedom bracket. Addition-
ally, a sixth degree (rotation) can be performed digitally.
The camera allows for simultaneous acquisition of colour
videos and normalized fluorescence images in real-time,
yielding a lateral resolution up to 66.58 mm and a variable
field of view (FOV) of 13.5 W  11 H to 115 W  95 H
(mm). A description in full detail is provided by Themelis
et al.27 The invisible NIRF imaging signal was digitally con-
verted into a pseudo-colour and superposed on a colour video
image of the operating field, allowing for real-time, intrao-
perative anatomical positioning of the fluorescence signal.Simulation of intraoperative NIRF imagingBreast phantoms with tumour-like NIR fluorescent aga-
rose inclusions were used to simulate and evaluate the poten-
tial of NIRF imaging applications in BCS (Figures 1 and 3).
In all phantoms, the location of the tumour-like fluorescent
inclusions was assessed preoperatively with non-invasive
NIRF imaging. In phantoms #1 and #2, the tumour-likentoms is shown for fluorescent agarose inclusions placed at varying depths
per second exposure time are depicted on the horizontal and vertical axis,
epth (mm) and full width at half maximum (pixels) on the horizontal and
h with the NIRF intraoperative camera system (C), the surgeon repeatedly
placed at 30 mm depth in breast phantom tissue. At 30, 27 and 24 mm in-
ected (normalized) for an exposure time of 1000 ms.
Figure 3. Overview of NIRF applications in breast-conserving surgery. In the case of relatively superficial lesions (2 cm), NIRF allows for preoperative
localization of fluorescent tumour-like inclusions (A). Intraoperative NIRF imaging guides the surgeon towards the tumour-like agarose inclusions
(B þ C) and allows for intraoperative assessment of surgical margin status (CIIeV) and detection of residual disease (CIII). Colour bars next to the colour
overlay indicate a threshold at 800 counts. Pixels with values above the threshold were superposed on the colour video (overlay). Exposure time was set to
150 ms for all images.
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ventional surgical equipment, guided solely by visual inspec-
tion, tactile information, and preoperatively obtained NIRF
imaging data. The surgeon was asked to indicate when he be-
lieved a complete excision of the tumour was reached. Sub-
sequently, the NIRF camera system was applied to assess
the feasibility of NIRF-guided macroscopic margin assess-
ment of the surgical cavity and excised tissue fragments. In
case of an incomplete excision, the surgeonwas asked to per-
form a re-excision under real-time NIRF guidance.
In phantoms #3 and #4, the tumour-like fluorescent in-
clusions were localized and excised under real-time NIRF
guidance. While approaching the tumour-like fluorescent
inclusions, the surgeon was supported with both visible
and audible information. In short, the detected fluorescence
signal was depicted on a TFT-screen and was made quanti-
tatively audible using a digitally generated sound-pitch. In
this approach, an increase in sound-pitch represents an in-
crease in fluorescence signal indicating the approximation
of a tumour-like fluorescent inclusion.ResultsICG fluorescence self-quenching in agaroseTo determine the optimal ICG concentration in agarose,
a serial range of increasing ICG concentrations was ana-
lyzed for fluorescence characteristics. The optimal fluores-
cence signal was observed at a concentration of
approximately 10 mM ICG (Figure 4). These results are
comparable to self-quenching characteristics of ICG as pre-
viously determined in gelatin.29Maximal penetration depth of ICG fluorescenceThe maximal tissue penetration depth of a detectable
fluorescent ICG inclusion was reached at a depth of
21 mm (Figure 2C and supplemental video 2).
Supplementary videos related to this article can be found
at doi:10.1016/j.ejso.2010.10.006.
Figure 4. Optimal ICG concentration in 2% agarose was determined in
breast phantom tissue. Seventeen different concentrations (each 10 ml,
ranging from 0.5 mM to 350 mM) were imaged at once with the intraoper-
ative NIRF camera system. Working distance 45 cm, field of view
160 W  130 H (mm), exposure time: 1000 ms.
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fluorescent agarose inclusions was performed in 4 different
breast phantoms. The various tumour-like inclusions posi-
tioned at a depth of 2.0 cm were detectable with the
NIRF camera system (Figure 3A-I). Tumour-like inclusions
positioned at depths of 3.0 and 4.0 cm could not be detected
preoperatively.
Tumour-like inclusions in phantom #1 and #2 were
excised using conventional techniques for tumour localiza-
tion. In phantom #1, one out of two tumour-like inclusions
proved to be only partially excised, as evidenced by a rem-
nant strong fluorescence signal in the surgical cavity de-
tected by the NIRF camera system (Figure 3C-III).
In phantom #2, the excision of one out of two inclusions
was found to be incomplete. In case of residual fluores-
cence, the surgeon could detect and excise (theranostic pro-
cedure) the remnant inclusion under real-time NIRF
guidance (Figure 3C-IV and supplemental video 1). In all
cases, NIRF-guided re-excision resulted in a complete exci-
sion, without the need for additional excision of large breast
phantom fragments (Figure 3C-V).
In phantoms #3 and #4, the tumour-like inclusions were
located (Figure 3B) and excised (Figure 3C) under real-
time NIRF guidance. Although the inclusion at 3.0 cm
depth in phantom #4 could not be detected preoperatively
(Figure 3B-I), it was detectable using the NIRF camera sys-
tem after an incision of approximately 1 cm of superficial
phantom tissue (Figure 3B-II). In phantom #3, no residual
tumour-like inclusion material could be detected afterinitial NIRF-guided excision, while the excision of one
out of two irregular inclusions in phantom #4 was found
to be incomplete. Again, subsequent NIRF-guided re-exci-
sion resulted in a complete excision.
During the surgical simulation procedure, the approxima-
tion of the surgeon towards tumour-like fluorescent agarose
inclusions was guided by both visual information on
a TFT-screen and audible sound-pitched information (Sup-
plemental videos 1e2). The approach resulted in a clear
change in the signal strength of the fluorescence image that
was accompanied with an increase of the sound pitch at
w15 mm prior to excision of the tumour-like agarose inclu-
sion. These signals assisted the surgeon in carefully advanc-
ing the margins.DiscussionTissue-like phantoms and tumour-like inclusionsThe composition of the breast phantoms was based on
data published by De Grand et al., who developed and val-
idated phantoms to mimic the basic optical characteristics
(absorption and scattering coefficients) of breast tissue.29
The absorption of photons by both cellular organelles and
blood was simulated by hemoglobin, which gives the phan-
toms a deep red colour.32,33 Additionally, Intralipid was
added to mimic scattering properties of breast tissue.28
In order to resemble the clinical situation as close as pos-
sible, tumour-like fluorescent agarose inclusions were incor-
porated in the breast phantoms. The agarose-based
inclusions simulate the firm-elastic consistency of tumour
tissue and allow for surgical margin status assessment,
both intraoperatively (NIRF-guided surgery) and ex vivo
(NIRF-guided macroscopic margin assessment). The rela-
tively low concentration of ICG used in this study resembles
the potential application of microdose tumour-targeted fluo-
rophores (ranging from 1 mM to 100 mM) in BCS.
Although the phantoms used in this study are homoge-
neous, and therefore do not possess the complex structures
that characterize mammary tissue, they do provide a tool
for assessing the value of theoretical assumptions and indi-
cate generally important features of future clinical NIRF
imaging applications in BCS.Near-infrared fluorescence imaging: strengths and
drawbacksNIRF imaging offers a promising technique for real-time
NIRF-guided surgery in BCS with little interference in the
standard surgical procedure or changes in the design of the
operating theatre. The technology is considered safe, fast,
makes use of non-ionizing radiation, and has a high resolu-
tion.3,10 However, NIRF imaging does have limitations orig-
inating from the intrinsic characteristics of light propagation
through tissue, including scattering and absorbance.17
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linear dependence of the signal detected and the depth of
the fluorescence activity, NIRF imaging by epi-illumination
with our current camera system seems of limited value for
preoperative localization of tumours. This applies in partic-
ular to situations where the tumour is located relatively
deep (>2 cm) in fat and glandular tissue of the breast. How-
ever, since the surgeon, by definition, will bring the area of
interest closer to the surface during surgery, our multispec-
tral NIRF camera system is well-suited for intraoperative
imaging applications.
NIRF imaging instruments designed for preoperative
imaging, e.g. the SoftScan (ART, Advanced Research Tech-
nologies, Saint-Laurent (Quebec), Canada), show penetra-
tion depths far superior (up to 15 cm) to intraoperative
imaging systems.34 This difference in penetration depth is
due to the application of different imaging strategies which
are largely incompatible with surgery, e.g. trans-illumina-
tion and the need for light-conducting liquid media.Non-specific versus tumour-targeted fluorophoresSeveral possibilities exist for delivering fluorophores to
the tumour. One possibility would be to inject a non-spe-
cific fluorophore (e.g. ICG) into the tumour under stereo-
tactic or ultrasonographic guidance.35 However, there are
some significant drawbacks to this approach. First, the in-
jection of the non-specific fluorophore into the tumour is
a critical step in the procedure and has to be very accurate
to minimize false-negative and false-positive results. Addi-
tionally, spillage/leakage of fluorophore within the mam-
mary gland during the procedure will decrease accuracy
of both localization of the tumour and macroscopic margin
assessment. Therefore, we believe NIRF-guided surgery
should ideally be combined with tumour-targeted fluoro-
phores, which provide molecularly-specific detection of
cancer cells. In these agents, the NIR fluorophore has
been conjugated to a specific targeting ligand or monoclo-
nal antibody. This allows for tumour-specific binding of
the fluorophore, increasing signal-to-noise (SN) ratios
and minimizing spillage of the fluorophore during the sur-
gical procedure.3,10 Several studies have shown the feasi-
bility of using tumour-targeted fluorophores in vivo to
image tumours intraoperatively, including the use of tu-
mour-targeted ICG-conjugated agents.5,9,22,25,26,36,37 How-
ever, there are some significant drawbacks, including the
heterogeneity of (breast) tumours which should be solved
before applying tumour-targeted NIRF imaging in the
clinic. In BCS, the preoperative biopsy taken prior to sur-
gery could provide important information on molecular
targets for NIRF imaging. As this biopsy is considered
standard practice, it will not require an additional invasive
procedure, while offering the possibility to determine the
expression of different kinds of molecular targets present
on the breast cancer cells by immunohistochemical analy-
sis. The surgeon could then look for NIRF agents suitedfor each individual tumour, offering a more patient-tai-
lored approach.
Conclusion
We have preclinically assessed the applicability of NIRF
imaging applications in BCS by exploiting tissue-simulat-
ing breast phantoms. NIRF-guided intraoperative tumour
localization and detection of remnant disease showed feasi-
ble. Clinical studies are needed to further validate these re-
sults for use in BCS.
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